Crowell & Moring Advises Cure Ventures in Series A Financing of Tortugas Neuroscience
Firm News | less than 1 min read | 04.21.26
Boston – April 21, 2026: Crowell & Moring advised founding investor Cure Ventures in the Series A financing of Tortugas Neuroscience, a neurology-focused biotech company.
Cure Ventures co-led the Series A round in partnership with The Column Group and AN Venture Partners. Proceeds from the financing will support Tortugas’ ongoing research and development initiatives regarding new and major neurology and neuropsychiatric disorders, including the completion of Phase 2 clinical trials for its two lead candidates.
The financing transaction was led by partner Kurt Machemer (Boston).
Read more here.
Insights
Firm News | 1 min read | 08.04.26
Crowell & Moring Represents Antares in $470 Million Series C
August 4, 2026: Crowell & Moring represented Antares, a nuclear fission energy company developing compact microreactors for defense and space applications, in connection with its $470 million Series C funding round. The round was co-led by Paradigm and Caffeinated Capital, with participation from Point72 Ventures, Shine Capital, Industrious Ventures, and others.
Firm News | 1 min read | 08.03.26
Crowell & Moring Partners Alex Lucas and Michael Samuels Named 2026 Law360 Rising Stars
Firm News | 1 min read | 07.30.26
Crowell & Moring Earns National Recognition in Managing IP’s 2026 USA IP Stars Rankings
Firm News | 2 min read | 07.29.26
